Role of LFA-3, ICAM-1, and MHC class I on the sensitivity of human tumor cells to LAK cells

Journal of Surgical Research

Volumn 60, Issue 1, 1996, Pages 129-136

  Gwin, John L ^a,c   Gercel Taylor, Cicek ^b,c   Taylor, Douglas D ^b,c   Eisenberg, Burton ^c  

^a UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

^b University of Louisville School of Medicine   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT GAMMA INTERFERON;

ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; CELL ADHESION; CELL MEDIATED CYTOTOXICITY; DAUDI CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA CELL; PRIORITY JOURNAL;

EID: 0030021258     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1996.0021     Document Type: Article

References (33)

1. Shaw, S., Ginther Luce, G. E., Quinones, R., Gress, R. E., Springer, T. A., and Sanders, M. E. Two antigen-independent adhesion pathways used by human cytotoxic T-cell clones. Nature (London) 323: 262, 1986.
2. Springer, T. A. Adhesion receptors of the immune system. Nature (London) 346: 425, 1990.
3. Quillet-Mary, A., Cavarec, L., Kermarrec, N., et al. Target lysis by human LAK cells is critically dependent upon target binding properties, LFA-1, LFA-3 and ICAM-1 are not the major adhesion ligands on targets. Int. J. Cancer 47: 473, 1991.
4. Grimm, E. A., Mazumder, A., Zhang, H. Z., and Rosenberg, S. A. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2 activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155: 1823, 1982.
5. Rosenberg, S. A., Lotze, M. T., Muul, L. M., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N. Engl. J. Med. 316: 889, 1987.
6. West, W. H., Tauer, K. W., Yannelli, G. D., et al. Constantinfusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med. 316: 898, 1987.
7. Itoh, K., Pellis, N. R., Balch, C. M. Monocyte-dependent, serumborn suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients. Cancer Immunol. Immunother. 29: 57, 1989.
8. Riley, L. B., Pellis, N. R., Schantz, S. P., Freedman, R. S., Balch, C. M., and Itoh, K. Humoral modulation of lymphokine-activated killer (LAK)-cell induction in humans: IgG-related and non-IgG inhibitors in sera from cancer patients. Int. J. Cancer 46: 785, 1990.
9. Ortaldo, J. R., Mason, A., and Overton, R. Lymphokine-activated killer cells: analysis of progenitors and effectors. J. Exp. Med. 164: 1193, 1986.
10. Phillips, J. H., and Lanier, L. L. Dissection of the lymphokine-activated killer phenomenon: relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J. Exp. Med. 164: 814, 1986.
11. Tilden, A., Itoh, K., and Balch, C. M. Human lymphokine-activated killer (LAK) cells: identificatyion of two types of effector cells. J. Immunol. 138: 1068, 1987.
12. Ljunggren, H-G., and Karre, K. In search of the 'missing self: MHC molecules and NK cell recognition. Immunol. Today 111: 237, 1990.
13. Storkus, W. J., Howell, D. N., Salter, R. D., Dawson, J. R., and Cresswell, P. NK susceptibility varies inversely with target cell class I HLA antigen expression. J. Immunol. 138: 1657, 1987.
14. Maio, M., Altomonte, M., Tatake, R., Zeff, A., and Ferrone, S. Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cell after induction of HLA Class I antigen expression by transfection with B2m gene. J. Clin. Invest. 88: 282, 1991.
15. Stam, N. J., Kast, W. M., Voordouw, A. C., et al. Lack of correlation between levels of MHC class I antigen and susceptibility to lysis of small cellular lung carcinoma (SCLC) by natural killer cells. J. Immunol. 142: 4113, 1989.
16. Timonen, T., Gahmberg, C. G., Patarroyo, M. Participation of CD11a-c/CD18. CD2, and RGD-binding receptors in endogenous interleukin-2-stimulated NK activity of CD3-negative large granular lymphocytes. Int. J. Cancer 46: 1035, 1990.
17. Rivoltini, L., Cattoretti, G., Arienti, F., et al. The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype. Int. J. Cancer 47: 746, 1991.
18. Correale, P., Procopis, A., Celio, L., et al. Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer and lymphokine-activated-killer-mediated cytotoxicity. Cancer Immunol. Immunother. 34: 272, 1992.
19. Fady, C., Gardner, A. M., Gera, J. F., and Licktenstein, A. Interferon-induced increase in sensitivity of ovarian cancer targets to lysis by lymphokine-activated killer cells: Selective effects on HER2/neu-overexpressing cells. Cancer Res. 52: 764, 1992.
20. Scheper, R. J., Dalton, W. S., Grogan, T. M., et al. Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK-and LAK-mediated cytotoxicity. Int. J. Cancer 48: 562, 1991.
21. Altomonte, M., Gloghini, A., Bertola, G., Gasparollo, A., Carbone, A., Ferrone, S., and Maio, M. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res. 53: 3343, 1993.
22. Naganuma, H., Kiessing, R., Patarroyo, M., Hansson, M., Handgretinger, R., and Gronberg, A. Increased susceptibility of IFN-gamma-treated neuroblastoma cells to lysis by lymphokine-activated killer cells: Participation of ICAM-1 induction on target cells. Int. J. Cancer 47: 527, 1991.
23. Wiebke, E. A., Custer, M. C., Rosenberg, S. A., and Lotze, M. T. Cytokines alter target cell susceptibility to lysis: I. evaluation of non major histocompatability complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing. J. Biol. Response Mod. 9: 113, 1990.
24. Trinchineri, G. Biology of natural killer cells. Adv. Immunol. 47: 187, 1989.
25. Kozlowski, J. M., Hart, I. R., Fidler, I. J., and Hanna, N. A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice. J. Natl. Cancer Inst. 72: 913, 1984.
26. Gercel-Taylor, C., Calaf, G., Hoffman, J. P., and Testa, J. R. Isolation of a malignant cell line from post-mastectomy seroma. Proc. Am. Assoc. Cancer Res. 33: 36, 1992.
27. Boyum, A. Isolation of mononuclear cells and granulocytes from human blood. Scan. J. Clin. Lab. Invest. 21(Suppl 97): 77, 1968.
28. Segal, D. M. Measurement of intercellular conjugates by flow cytometry. In J. E. Coligan, A. M. Kruisbeck, D. H. Margulies, E. M. Shevach, and W. Stroker, (Eds.) Current Protocols in Immunology, Vol. 1. New York: Wiley, 1991. 5.6.1.-5.6.8.
29. Miyatake, S., Kikuchi, H., Oda, Y., et al. Decreased susceptibility of lined gliosarcoma cells to lymphokine-activated killer cell cytolysis by gamma-interferon treatment. Cancer Res. 50: 596, 1990.
30. Weil-Hillman, G., Fisch, P., Prieve, A. F., Sosman, J. A., Hank, J. A., Sondel, P. M. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and Leu 19 antigens but negative expression of CD16 antigens. Cancer Res. 49: 3680, 1989.
31. Gregory, C. D., Murray, R. J., Edwards, C. F., and Rickinson, A. B. Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr Virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J. Exp. Med. 167: 1811, 1988.
32. Makgoba, M. W., Sanders, M. E., and Shaw, S. The CD-2-LFA-3 and LFA-1-ICAM pathways: Relevance to T-cell recognition. Immunol. Today 10: 417, 1989.
33. Johnson, J. P. Cell adhesion molecules of the immunoglobulin supergene family and their role in malignant transformation and progression to metastatic disease. Cancer Met. Rev. 10: 11, 1991.